drugset / Trial / NCT05109949

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

NCT05109949

RandomizedParallel-groupTriple-blindOther

Summary

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration, but there's not enough studies about acute effects in early administration.

Timeline

Start
2020-03-30
Primary completion
2022-06-01
Completion
2022-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Empagliflozin Small molecule 25 mg